Five-year research project unites 42 public and private partners across 17 countries to conduct 22 clinical studies involving 14,000+ patients; first patients will be enrolled this month
-
asserted
patients → unite → patients
Project aims to help cardiac patients avoid deterioration through early, personalized interventions delivered across the cardiac care journey
-
asserted
patients → aim → journey
Interventions will be co-created with patients and designed to systematically address socioeconomic, sex- and gender-related and digital access gaps
-
asserted
Interventions → co → gaps
With a total budget of EUR 27.6 million, the project is co-
asserted
project → co → million
Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the launch of the five-year EXIT-CVD research project, co-funded by the European Union Innovative Health Initiative (IHI) and the industry partners.
asserted
Philips → announce → Initiative
The research consortium is led by University Medical Center Groningen (UMCG) and Philips, and aims to transform how cardiovascular disease is detected, monitored and treated.
asserted
disease → lead → Groningen
It will do so by identifying and acting on three key exit points along the cardiac care journey: preventing disease before it develops (early exit), reversing disease progression (mid exit), or halting progression in advanced stages (late exit).
asserted
it → do → stages
Patient enrollment for the first of the 22 clinical studies will begin this month.
asserted
enrollment → begin → studies
Cardiovascular health is fundamental to overall health and well-being, yet more than 60 million people in the European Union are living with cardiovascular disease.
asserted
people → live → disease
For many, the condition significantly reduces quality of life and well-being.
asserted
condition → reduce → life
Without early detection, timely diagnosis and appropriate treatment, cardiovascular disease can progress silently from early risk factors to established disease and ultimately, cardiac events that may lead to premature death.
uncertain
that → progress → death
“Our vision is a future where heart disease is no longer an irreversible pathway,” said Professor Pim van der Harst, Project Coordinator of EXIT-CVD and Head of Cardiology at the University Medical Center Groningen.
asserted
Harst → say → Groningen
“By understanding both the biological and social drivers of cardiovascular disease, and deploying integrated innovations across diagnostics, monitoring, and care, we can empower patients and clinicians to exit the disease continuum before it’s too late.”
asserted
it → understand → continuum
“For more than 30 years, we have viewed cardiovascular disease as a continuous journey, from risk factors such as hypertension, to atherosclerosis, a first cardiac event and ultimately, for many patients, heart failure,” said Robin Nijveldt, Chief of Cardiology at UMC Utrecht.
asserted
Nijveldt → view → Utrecht
“Yet most of us improve care within our own specialty and rarely have a complete view of the patient’s experience.
asserted
most → improve → experience
EXIT-CVD is an ambitious effort to build that holistic view together, helping transform cardiac care for millions of patients across Europe.
asserted
CVD → build → Europe
The EXIT-CVD clinical studies will focus on the three key exit points along the cardiac care journey: early detection through digital monitoring (early exit), personalized risk assessment and targeted interventions (mid exit), and advanced therapies to support recovery in later-stage disease (late exit).
asserted
studies → focus → disease
By combining diagnostics, digital tools and advanced therapeutic approaches, EXIT-CVD aims to deliver actionable, evidence-based strategies that can be implemented across diverse healthcare systems in Europe.
asserted
that → combine → Europe
Innovation that reaches everyone
New diagnostics and digital tools often reach well-resourced populations first, widening gaps in access and outcomes.
asserted
diagnostics → reach → access
The project will therefore embed implementation science and equity-by-design principles to ensure that the solutions are scalable, sustainable, and accessible to all relevant populations, including those historically underserved.
asserted
solutions → embed → those
A digitally enabled, FAIR-compliant data platform aligned with the European Health Data Space (EHDS) will support the integration, evaluation, and real-world scalability of the project's innovations.
asserted
platform → enable → innovations
“The EXIT-CVD project focuses on three critical stages of cardiovascular disease progression where technology can make the greatest impact: preventing disease before it develops, reversing its progression and improving care for people with advanced disease,” said Bert van Meurs, Chief Business Leader Diagnosis and Treatment, Image Guided Therapy at Royal Philips.
asserted
Meurs → focus → Philips
“Together with our consortium partners, we are exploring innovations ranging from contactless vital signs monitoring for early detection of patient deterioration to advanced spectral CT imaging that reveals tissue characteristics beyond anatomy.
asserted
that → explore → anatomy
These technologies have the potential to give clinicians deeper insights and support earlier, more informed cardiac care.”
asserted
technologies → have → care
The EXIT-CVD research consortium will conduct a total of 22 clinical studies involving more than 14,000 patients across Europe, including:
- Camera-Based In-Hospital Monitoring (CARDIO-CAM study): Deployment and evaluation of an unobtrusive, video-based patient monitoring system that continuously captures cardiorespiratory signals and relevant clinical context.
asserted
that → conduct → signals
The IHI EXIT-CVD public-private partnership comprises 42 partner organizations from 17 countries:
asserted
partnership → comprise → countries
Industry partners: Philips, Circle CVI, GE Healthcare, Siemens Healthineers, HeartBeam, Medtronic, Huawei, XVIVO Perfusion, AstraZeneca, Cardiomed, Megi Health, Viatris, Cordys, Novartis, Corbotics, ZOLL, Sanofi, Repairon, Johnson & Johnson MedTech Heart Recovery, Onsentia, and CogStack
- Healthcare consultancy: Bridg Ou and IQVIA Solutions
- Patient organization: Stichting VrouwenHart
- Medical association: European Society of Cardiology (ESC)
This project is supported by the Innovative Health Initiative Joint Undertaking (IHI JU) under grant agreement No 101253160.
asserted
project → support → No
The JU receives support from the European Union’s Horizon Europe research and innovation program and COCIR, EFPIA, Europa Bío, MedTech Europe, and Vaccines Europe.
asserted
JU → receive → program
Views and opinions expressed are those of the author(s) only and do not necessarily reflect those of the aforementioned parties.
asserted
Views → express → parties
Neither of the aforementioned parties can be held responsible for them.
asserted
Neither → hold → them
The opinions and clinical experiences presented herein are specific to the featured clinician(s) and are for information purposes only.
asserted
opinions → present → purposes
Individual results may vary depending on a variety of patient-specific attributes and related factors.
uncertain
results → vary → attributes
Nothing in this article is intended to provide specific medical advice or to take the place of written law or regulations.
asserted
Nothing → intend → law
For further information, please contact:
Joost Maltha
Philips Global External Relations
Tel.: +31 6 1055816
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.
Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health.
asserted
company → contact → health
Philips generated 2025 sales of EUR 18 billion and employs approximately 63,700 employees with sales and services in more than 100 countries.
asserted
Philips → generate → countries
News about Philips can be found at www.philips.com/newscenter.
asserted
News → find → www.philips.com/newscenter
The Aporia
